Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead product candidate is AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is currently in a Phase 2 clinical trial for treating inflammatory diseases. The company operates in the United States and is dedicated to addressing unmet medical needs in the field of inflammation.

Avalo Therapeutics is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol AVTX. The company trades in U.S. dollars (USD), as it is headquartered in the United States and its securities are traded on a U.S. exchange. Investors can buy and sell AVTX shares through brokerage accounts that have access to Nasdaq.

Avalo Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies, particularly in the area of immune-mediated inflammatory diseases. The company's work involves advanced biological approaches, such as monoclonal antibodies, to target specific pathways in the immune system.

Avalo Therapeutics is headquartered in Wayne, Pennsylvania, United States. The company was incorporated in 2011 and was formerly known as Cerecor Inc. before rebranding to Avalo Therapeutics in August 2021. This rebranding reflected a strategic shift in focus toward developing IL-1β-based treatments for inflammatory diseases.

Avalo Therapeutics' main product candidate is AVTX-009, a humanized monoclonal antibody designed to bind to interleukin-1β (IL-1β), a key protein involved in inflammation. AVTX-009 is currently in Phase 2 clinical trials for the treatment of immune-mediated inflammatory diseases. The company is developing this therapy to address conditions where IL-1β plays a central role in disease pathology.